Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in <i>KRAS-</i>mutated non-small cell lung cancer with <i>STK11</i>, <i>KEAP1,</i> or <i>TP53</i> comutations: subgroup results from the phase III IMpower150 trial

Abstract

These analyses support previous findings of mutation of <i>STK11</i> and/or <i>KEAP1</i> as poor prognostic indicators. While clinical efficacy favored ABCP and ACP vs BCP in these mutational subgroups, survival benefits were greater in the m<i>KRAS</i> and <i>KEAP1</i>-WT and <i>STK11</i>-WT population vs m<i>KRAS</i> and m<i>KEAP1</i> and m<i>STK11</i> population, suggesting both prognostic and predictive effects. Overall, these results suggest that atezolizumab combined with bevacizumab and chemotherapy is an efficacious first-line treatment in metastatic NSCLC subgroups with m<i>KRAS</i> and co-occurring <i>STK11</i> and/or <i>KEAP1</i> or <i>TP53</i> mutations and/or high PD-L1 expression.